Novel Therapies for Sleep Apnea-The Implants Have Arrived

Positive airway pressure (PAP) therapy has been the standard treatment of choice for sleep disordered breathing, with 29-83% of patients being noncompliant. With the advent of newly Food and Drug Adminisatration (FDA)-approved implantable stimulators for treating sleep disordered breathing in a frac...

Full description

Saved in:
Bibliographic Details
Published inThe Neurodiagnostic journal Vol. 58; no. 2; p. 116
Main Authors Valladares, Edwin M, Hammond, Terese C
Format Journal Article
LanguageEnglish
Published United States 03.04.2018
Subjects
respicardia remedē system
Inspire upper airway stimulation therapy
Central sleep apnea
implant
sleep apnea
Online AccessGet more information

Cover

More Information
Summary:Positive airway pressure (PAP) therapy has been the standard treatment of choice for sleep disordered breathing, with 29-83% of patients being noncompliant. With the advent of newly Food and Drug Adminisatration (FDA)-approved implantable stimulators for treating sleep disordered breathing in a fraction of noncompliant PAP therapy patients, the landscape of sleep medicine and sleep technology is changing to narrow the gap between compliant and non-compliant patients. The remedē® System for treating central sleep apnea and the Inspire® upper airway stimulation (UAS) therapy for treating obstructive sleep apnea are providing new tools for sleep physicians, elevating sleep technologists' expertise, and paving the way for personalized medicine.
ISSN:2164-6821
DOI:10.1080/21646821.2018.1475805